Comparison of the prognostic effect of sarcopenia on atezolizumab plus bevacizumab and lenvatinib therapy in hepatocellular carcinoma patients.

Katsuya ToshidaShinji ItohTakahiro TomiyamaAkinari MorinagaYukiko KosaiTakahiro TominoTakeshi KuriharaYoshihiro NagaoKazutoyo MoritaNoboru HaradaTomoharu Yoshizumi

Published in: JGH open : an open access journal of gastroenterology and hepatology (2022)

In ATZ/BEV therapy, sarcopenia does not determine prognosis, and therapeutic efficacy can be expected even in cases of sarcopenia.

Keyphrases

skeletal muscle
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
community dwelling
stem cells
bone marrow
mesenchymal stem cells
patient reported